ADC Pipeline Battlefield: Antibody-Drug Conjugate Competitive Intelligence and Market Leadership Analysis; Comprehensive Assessment of Trop-2, HER2, and Novel Target Landscapes with Commercial Strategy Implications
The Antibody-Drug Conjugate (ADC) market is undergoing a profound transformation, evolving into a cornerstone of modern oncology. This explosive growth is projected to expand the market from approximately $10–$13.5 billion in 2023 to a valuation as high as $50 billion by 2030, driven by a 14-15% CAG ...
